Durvalumab in Combination With Trastuzumab in HER2‐Positive Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Phase Ib Trial of Durvalumab in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)
Oncologist 2019 Aug 16;[EPub Ahead of Print], S Chia, PL Bedard, J Hilton, E Amir, K Gelmon, R Goodwin, D Villa, M Cabanero, D Tu, M Tsao, L SeymourFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.